CSPC Pharmaceutical Group Dirección
Dirección controles de criterios 2/4
El CEO de CSPC Pharmaceutical Group's es Cuilong Zhang , nombrado en May 2022, tiene una permanencia de 1.92 años. compensación anual total es CN¥10.68M, compuesta por 6.5% salario y 93.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.034% de las acciones de la empresa, por valor de HK$24.00M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 9.6 años, respectivamente.
Información clave
Cuilong Zhang
Chief Executive Officer (CEO)
CN¥13.5m
Compensación total
| Porcentaje del salario del CEO | 5.1% |
| Permanencia del CEO | 2yrs |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 9.7yrs |
Actualizaciones recientes de la dirección
Recent updates
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29
There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price
Oct 18CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt
Sep 15CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10
Aug 26CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At HK$0.10
May 27CSPC Pharmaceutical Group (HKG:1093) Has Announced That It Will Be Increasing Its Dividend To HK$0.10
Apr 27CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To HK$0.10
Apr 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | CN¥13m | CN¥693k | CN¥6b |
| Sep 30 2023 | n/a | n/a | CN¥6b |
| Jun 30 2023 | n/a | n/a | CN¥6b |
| Mar 31 2023 | n/a | n/a | CN¥6b |
| Dec 31 2022 | CN¥11m | CN¥693k | CN¥6b |
| Sep 30 2022 | n/a | n/a | CN¥6b |
| Jun 30 2022 | n/a | n/a | CN¥6b |
| Mar 31 2022 | n/a | n/a | CN¥6b |
| Dec 31 2021 | CN¥9m | CN¥693k | CN¥6b |
| Sep 30 2021 | n/a | n/a | CN¥6b |
| Jun 30 2021 | n/a | n/a | CN¥6b |
| Mar 31 2021 | n/a | n/a | CN¥5b |
| Dec 31 2020 | CN¥9m | CN¥693k | CN¥5b |
| Sep 30 2020 | n/a | n/a | CN¥4b |
| Jun 30 2020 | n/a | n/a | CN¥4b |
| Mar 31 2020 | n/a | n/a | CN¥4b |
| Dec 31 2019 | CN¥7m | CN¥693k | CN¥4b |
| Sep 30 2019 | n/a | n/a | CN¥4b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥3b |
| Dec 31 2018 | CN¥4m | CN¥298k | CN¥3b |
Compensación vs. Mercado: La compensación total de Cuilong($USD1.48M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD924.91K).
Compensación vs. Ingresos: La compensación de Cuilong ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.
CEO
Cuilong Zhang (54 yo)
2yrs
Permanencia
CN¥13,472,000
Compensación
Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 27.1yrs | CN¥26.68m | 23.71% CN¥ 19.3b | |
| Vice-Chairman & CEO | 2yrs | CN¥13.47m | 0.034% CN¥ 27.4m | |
| Executive Director & Chief Scientist | 6.4yrs | CN¥9.42m | 0.038% CN¥ 30.9m | |
| Executive Director | no data | CN¥6.26m | 0.055% CN¥ 44.9m | |
| Executive Director | no data | CN¥4.92m | 0.013% CN¥ 10.3m | |
| Executive Director | no data | CN¥5.74m | 0.013% CN¥ 10.3m | |
| Executive Director | no data | CN¥4.90m | 0.013% CN¥ 10.3m | |
| Executive Director | no data | CN¥7.44m | sin datos | |
| Executive Director | no data | CN¥4.02m | 0.024% CN¥ 19.2m | |
| Company Secretary | 3.3yrs | sin datos | sin datos |
3.3yrs
Permanencia media
55.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 1093 se considera experimentado (4.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 27.1yrs | CN¥26.68m | 23.71% CN¥ 19.3b | |
| Vice-Chairman & CEO | 5.8yrs | CN¥13.47m | 0.034% CN¥ 27.4m | |
| Executive Director & Chief Scientist | 6.4yrs | CN¥9.42m | 0.038% CN¥ 30.9m | |
| Executive Director | 18.4yrs | CN¥6.26m | 0.055% CN¥ 44.9m | |
| Executive Director | 17.6yrs | CN¥4.92m | 0.013% CN¥ 10.3m | |
| Executive Director | 13.6yrs | CN¥5.74m | 0.013% CN¥ 10.3m | |
| Executive Director | 12.3yrs | CN¥4.90m | 0.013% CN¥ 10.3m | |
| Executive Director | 5.8yrs | CN¥7.44m | sin datos | |
| Executive Director | 3.5yrs | CN¥4.02m | 0.024% CN¥ 19.2m | |
| Independent Non-Executive Director | 3.3yrs | CN¥340.00k | sin datos | |
| Independent Non-Executive Director | 11.4yrs | CN¥142.00k | sin datos | |
| Independent Non-Executive Director | 7.9yrs | CN¥142.00k | sin datos |
9.7yrs
Permanencia media
55.5yo
Promedio de edad
Junta con experiencia: La junta directiva de 1093 se considera experimentada (9.6 años de antigüedad promedio).